Trial data explains failure of invasive E coli vaccine
A phase 3 trial for ExPEC9V, a vaccine developed by Janssen and Sanofi to prevent invasive E. coli disease (IED) in older adults, was discontinued after showing only 14.6% efficacy. The trial, involving 17,000 participants, found that while the vaccine induced a strong antibody response, it did not prevent IED cases. Investigators suggest the immune response may not have been sufficient for clinical protection. Further analysis is needed to understand the failure.
How this was made
The 30-second read
Why it matters
The disclosed efficacy of 14.6% indicates the vaccine will not proceed to market, prompting potential write‑downs and pipeline reassessment for both companies.
Market read
The trial failure is a material negative catalyst for JNJ and SNY, likely weighing on their shares in the short term.
What to watch
The trial still demonstrated strong antibody responses and safety, which could support alternative indications.
Background
The ExPEC9V vaccine targets extraintestinal pathogenic E. coli, a major cause of sepsis in older adults. The trial enrolled >17,000 participants across 20 countries.
Ticker impact
Sanofi co‑developed the ExPEC9V vaccine whose Phase 3 trial showed only 14.6% efficacy and was discontinued.
likely pressure as investors reassess the infectious‑disease portfolio
Sanofi's partnership with Janssen did not deliver a viable vaccine, reducing future revenue prospects.
Market effects
Potential setback for the infectious‑disease vaccine segment, may shift focus to other candidates.
Limited to markets where Janssen and Sanofi have significant vaccine operations.
Modest; the failure affects two large pharma stocks but does not alter broader market direction.
Counterpoint
Some investors may view the modest efficacy as a stepping stone for future iterations.
Key entities
- companyJanssen Pharmaceuticals
Johnson & Johnson's pharmaceutical division, co‑developer of ExPEC9V.
- companySanofi
French pharma partner in the ExPEC9V vaccine development.
